Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Depreciation & Amortization (CF) (2021 - 2025)

SAB Biotherapeutics (SABS) has disclosed Depreciation & Amortization (CF) for 5 consecutive years, with $746830.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) fell 1.5% year-over-year to $746830.0, compared with a TTM value of $3.0 million through Dec 2025, down 36.17%, and an annual FY2025 reading of $3.0 million, down 36.17% over the prior year.
  • Depreciation & Amortization (CF) was $746830.0 for Q4 2025 at SAB Biotherapeutics, roughly flat from $743764.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $2.0 million in Q1 2024 and bottomed at $235959.0 in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $804671.0, with a median of $757415.5 recorded in 2024.
  • The sharpest move saw Depreciation & Amortization (CF) soared 189.39% in 2022, then crashed 62.17% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $619984.0 in 2021, then surged by 49.9% to $929379.0 in 2022, then decreased by 2.99% to $901547.0 in 2023, then decreased by 15.9% to $758236.0 in 2024, then dropped by 1.5% to $746830.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for SABS at $746830.0 in Q4 2025, $743764.0 in Q3 2025, and $752811.0 in Q2 2025.